VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE)

35 filings reported holding VYNE - VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share as of Q1 2024.
VYNE Therapeutics Inc. - Common Stock, par value $0.0001 per share (VYNE) has 28 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 6.4M shares of 16.7M outstanding shares and own 38.44% of the company stock.
Largest 10 shareholders include Cormorant Asset Management, LP (1.39M shares), CITADEL ADVISORS LLC (1.18M shares), Parkman Healthcare Partners LLC (696K shares), DSC Advisors, L.P. (696K shares), Palo Alto Investors LP (445K shares), AlphaCentric Advisors LLC (445K shares), Exome Asset Management LLC (415K shares), Schonfeld Strategic Advisors LLC (220K shares), Royal Bank of Canada (175K shares), and ADAR1 Capital Management, LLC (110K shares).
This table shows the top 28 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.